Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone

Journal of Clinical Oncology

Volumn 24, Issue 13, 2006, Pages 2084-2091

  Lee, James J ^a   Low, Jennifer A ^a   Croarkin, Earllaine ^a   Parks, Rebecca ^a   Berman, Arlene W ^a   Mannan, Nitin ^a   Steinberg, Seth M ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPOTHILONE DERIVATIVE; IXABEPILONE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HAND FUNCTION; HUMAN; MULTIPLE CYCLE TREATMENT; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EPOTHILONES; FEMALE; HUMANS; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES;

EID: 33646449521     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.2820     Document Type: Article

References (57)

1. Von Hoff DD: The taxoids: Same roots, different drugs. Semin Oncol 24:S13-3-S13-10, 1997
2. Theiss C, Meller K: Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res 299:213-224, 2000
3. Nakata T, Yorifuji H: Morphological evidence of the inhibitory effect of Taxol on the fast axonal transport. Neurosci Res 35:113-122, 1999
4. Roytta M, Horwitz SB, Raine CS: Taxol-induced neuropathy: Short-term effects of local injection. J Neurocytol 13:685-701, 1984
5. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0, December 12, 2003. http://ctep.cancer.gov/forms/CTCAEv3.pdf
6. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
7. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
8. Postma TJ, Heimans JJ: Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509-513, 2000
9. Postma TJ, Heimans JJ, Muller MJ, et al: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744, 1998
10. Brundage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 85:1138-1148, 1993
11. Forsyth PA, Balmaceda C, Peterson K, et al: Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 35:47-53, 1997
12. Kamei N, Yamane K, Nakanishi S, et al: Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening. J Diabetes Complications 19:47-53, 2005
13. Padua L, Aprile I, Saponara C, et al: Multiperspective assessment of peripheral nerve involvement in diabetic patients. Eur Neurol 45:214-221, 2001
14. Perkins BA, Olaleye D, Zinman B, et al: Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 24:250-256, 2001
15. Jebsen RH, Taylor N, Trieschmann RB, et al: An objective and standardized test of hand function. Arch Phys Med Rehabil 50:311-319, 1969
16. Casanova JE, Casanova JS, Young MJ: Hand function in patients with diabetes mellitus. South Med J 84:1111-1113, 1991
17. Ruff RM, Parker SB: Gender- and age-specific changes in motor speed and eye-hand coordination in adults: Normative values for the Finger Tapping and Grooved Pegboard Tests. Percept Mot Skills 76:1219-1230, 1993
18. Meneilly GS, Cheung E, Tessier D, et al: The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117-M121, 1993
19. Trites R: Neuropsychological Test Manual. Ottawa, Ontario, Canada, Royal Ottawa Hospital, 1977
20. Hurvitz EA, Richardson JK, Werner RA: Unipedal stance testing in the assessment of peripheral neuropathy. Arch Phys Med Rehabil 82:198-204, 2001
21. Lafond D, Corriveau H, Prince F: Postural control mechanisms during quiet standing in patients with diabetic sensory neuropathy. Diabetes Care 27:173-178, 2004
22. Nardone A, Schieppati M: Group II spindle fibers and afferent control of stance: Clues from diabetic neuropathy. Clin Neurophysiol 115:779-789, 2004
23. Goodin S, Kane MP, Rubin EH: Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22:2015-2025, 2004
24. Abraham J, Agrawal M, Bakke S, et al: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21:1866-1873, 2003
25. Eng C, Kindler HL, Nattam S, et al: A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15:928-932, 2004
26. Lee D: Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer. Clin Prostate Cancer 3:80-82, 2004
27. Mani S, McDaid H, Hamilton A, et al: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289-1298, 2004
28. Okuno S, Maples WJ, Mahoney MR, et al: Evaluation of epothilone B analog in advanced soft tissue sarcoma: A phase II study of the phase II consortium. J Clin Oncol 23:3069-3073, 2005
29. Smaletz O, Galsky M, Scher HI, et al: Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 14:1518-1524, 2003
30. Zhuang SH, Menefee M, Kotz H, et al: A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol 22:394s, 2004 (suppl 14; abstr 4550)
31. McDaid HM, Mani S, Shen HJ, et al: Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8:2035-2043, 2002
32. Galsky MD, Small EJ, Oh WK, et al: Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446, 2005
33. Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005
34. Roche HH, Cure H, Bunnell C, et al: A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 22:18, 2003 (abstr 69)
35. Thomas E, Tabernero J, Fornier M, et al: A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 22:8, 2003 (abstr 30)
36. Thomas E, Bunnell CA, Vahdat LT, et al: A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. Breast Cancer Res Treat 82:S83, 2003 (suppl 1, abstr 350)
37. Hussain M, Faulkner J, Vaishampayan U, et al: Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC): A Southwest Oncology Group Study (S0111). J Clin Oncol 22:384s, 2004 (suppl 14; abstr 4510)
38. Vansteenkiste J, Breton J, Sandler A: A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung 932 cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 22: 626, 2003 (abstr 2519)
39. Whitehead RP, McCoy SA, Rivkin SE, et al: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. J Clin Oncol 22:316s, 2004 (suppl 14; abstr 4012)
40. Fojo AT, Menefee ME, Poruchynsky M, et al: A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol 23:388s, 2005 (suppl 16; abstr 4541)
41. O'Connor O, Straus D, Moskowitz C, et al: Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS-247550 induces major and durable remissions in very drug resistant disease. J Clin Oncol 23:577s, 2005 (suppl 16; abstr 6569)
42. Smith SM, Pro B, van Besien K, et al: A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. J Clin Oncol 23:591s, 2005 (suppl 16; abstr 6625)
43. Singh DA, Kindler HL, Eng C, et al: Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer. Proc Am Soc Clin Oncol 22:281, 2003 (abstr 1127)
44. Llombart Cussac A, Baselga J, Manikhas G, et al: Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol 23:25s, 2005 (suppl 16; abstr 586)
45. Pavlick AC, Millward M, Farrell K, et al: A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). J Clin Oncol 22:720s, 2005 (suppl 16; abstr 7542)
46. National Cancer Institute: Common Toxicity Criteria v2.0 (April 30, 1999). http://ctep.cancer.gov/reporting/CTC-3test.html
47. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
48. Jeng C, Michelson J, Mizel M: Sensory thresholds of normal human feet. Foot Ankle Int 21:501-504, 2000
49. Birke JA, Brandsma JW, Schreuders TA, et al: Sensory testing with monofilaments in Hansen's disease and normal control subjects. Int J Lepr Other Mycobact Dis 68:291-298, 2000
50. Liveson JA, Ma DM: Laboratory Reference for Clinical Neurophysiology. Philadelphia, PA, F.A. Davis Company, 1992
51. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
52. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
53. Roché H, Delord JP, Bunnell CA, et al: Phase II studies of the novel epothilone BMS-247550 in patients (pts) with taxane-naïve or taxane-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 21:59a, 2002 (abstr 223)
54. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
55. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068, 2004
56. Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22:6s, 2004 (suppl 14; abstr 512)
57. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998